Indication
Treatment of adults with moderate-to-severe prurigo nodularis (PN) who are candidates for systemic therapy.
Medicine details
- Medicine name:
- nemolizumab (Nemluvio)
- SMC ID:
- SMC2382
- Pharmaceutical company
- Galderma (UK) Ltd
- BNF chapter
- Skin
- Submission type
- Full
- Publication due date:
- TBC
- SMC meeting date:
- TBC
- Patient group submission deadline:
- TBC